Questions for the Harvard case “Metabical: Pricing‚ Packaging‚ and Demand Forecasting for a New Weight-Loss Drug” For March 20‚ write responses to the following questions for the Metabical case. 1) How is Metabical different from the existing weight-loss options? How is it better or worse than the other options? Metabical is the first prescription drug approved specifically for overweight individuals (BMI between 25 and 30)‚ those individuals who have weight-loss goals of approximately
Premium Obesity Weight loss Nutrition
272593 BUS 474 A 02/14/2011 Metabical After spending millions of dollars for ten years in research and development‚ Metabical was finally able to receive FDA approval‚ making it the first and only drug to receive FDA approval to meet the needs of customers who have been trying to lose weight. Like with any other new product‚ numerous issues need to be considered before Metabical is actually introduced in the market. Decisions about pricing‚ packaging and demand forecast of the product are key
Premium Obesity Pharmacology
B Problem Statement Barbara Printup must determine the packaging for Metabical that will best capture the accurately forecasted demand of the target market. With many substitutes for weight loss in a variety of packages and price points‚ it will be important to create a package that can be priced in a way to both drive sales and continued use of the 12-week drug. Printup must also develop a pricing model to align with the packaging and the price expectations of the target market. Since this is
Premium Price Marketing Price point
Metabical (Case study) Case Facts • Metabical is a prescription drug produced by Cambridge Sciences Pharmaceuticals (CSP) for weight loss. • It was the first and only prescription drug to obtain FDA approval for weight loss (overweight category) drug. • The company had conducted an elaborate market research program for identifying the target segment and positioning the product. • Competitors: FDA approved OTC drug Alli. • Marketing strategy: – DTC advertising- celebrity endorser‚ TV‚ radio‚
Premium Obesity Food and Drug Administration Marketing
[pic] Business Case Metabical Version 1.0 ● October 21th‚ 2010 [pic] Work Group Metabical – Business Case |VERSION: 1 |REVISION DATE: 10/21/2010 | |Team Members | |Eduardo Lins |[Email] |[Telephone]
Premium Obesity
2) How should Printup think about the segmentation of potential Metabical consumers? Who is the optimal target consumer? The book of Marketing Management defines “Market Segmentation” as the process of dividing the market into group(s) of similar consumers and selecting the most appropriate to serve. Eventually‚ the selected group will be called the target market. According to this definition and the case on hand‚ Printup must decide on the parameters according to which she should start the segmentation
Premium Obesity Marketing Weight loss
• What is the decision making process for Metabical? ◦ Who is involved? ◦ What role do they play? ◦ What are the stages in the process? In the launch of Metabical for the US market‚ several marketing decisions need to be made to bring a viable product into the market to maximize market penetration and gross margins over the PLC and to best serve the needs of the customers The players are • Health Care Professionals ◦ Will prescribe Metabical to their patients ◦ Can influence Insurance Companies
Premium Marketing
Metabical Analysis 1) Benefits: * All other Weight-Loss Options in Exhibit 2 are more expensive that the target $30/ month out of pocket cost. * No other weight loss option offers cost containment cards. * No other product combines two mechanisms for weight loss: Metabical combines two pharmacologic mechanisms to produce weight loss: Fat blocker‚ meditonan and appetite suppressant‚ calosera. Due to the dual mechanism‚ the medications can be dosed in lower levels and therefore have
Premium Obesity Prescription drug Pharmacology
In 2008‚ a marketing and positioning strategy was needed for Cambridge Sciences Pharmaceutical’s (CSP) new weight loss drug called Metabical. Metabical was touted as being a revolutionary weight loss drug with fewer negative side effects than the usual medicinal weight loss remedies. Metabical has many levels of decision-makers – both internal and external. CSP’s senior director of marketing‚ Barbara Printup likely reports to the company’s board of directors for her ultimate authority. Printup
Premium Marketing Weight loss Obesity
healthcare company that had completed successful clinical trials for its newest weight loss prescription drug‚ Metabical. With the final FDA approval expected‚ Metabical’s launch was set for January 2009 and a clear marketing communications strategy needed to be in place before the launch. With 10 years and $400 million spent on research and development‚ it was imperative that CSP positions Metabical correctly in the marketplace. Optimal segmentation‚ targeting‚ and positioning were important factors to
Premium Obesity Food and Drug Administration Health care